These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

736 related items for PubMed ID: 33068050

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Establishment and characterisation of six human biliary tract cancer cell lines.
    Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, Kim SW, Park YH, Hwang JH, Yoon YB, Park JG.
    Br J Cancer; 2002 Jul 15; 87(2):187-93. PubMed ID: 12107841
    [Abstract] [Full Text] [Related]

  • 3. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 4. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
    Caca K, Feisthammel J, Klee K, Tannapfel A, Witzigmann H, Wittekind C, Mössner J, Berr F.
    Int J Cancer; 2002 Feb 01; 97(4):481-8. PubMed ID: 11802210
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mutational spectrum and precision oncology for biliary tract carcinoma.
    Lin J, Cao Y, Yang X, Li G, Shi Y, Wang D, Long J, Song Y, Mao J, Xie F, Bai Y, Zhang L, Yang X, Wan X, Wang A, Guan M, Zhao L, Hu K, Pan J, Huo L, Lu X, Mao Y, Sang X, Zhang H, Wang K, Wang X, Zhao H.
    Theranostics; 2021 Feb 01; 11(10):4585-4598. PubMed ID: 33754015
    [Abstract] [Full Text] [Related]

  • 7. [Gallbladder and bile duct carcinoma. Biology and pathology].
    Tannapfel A, Wittekind C.
    Internist (Berl); 2004 Jan 01; 45(1):33-41. PubMed ID: 14735242
    [Abstract] [Full Text] [Related]

  • 8. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN.
    Hepatology; 2021 Oct 01; 74(4):1914-1931. PubMed ID: 33884649
    [Abstract] [Full Text] [Related]

  • 9. Familial Risk of Biliary Tract Cancers: A Population-Based Study in Utah.
    Samadder NJ, Smith KR, Wong J, Hanson H, Boucher K, Burt RW, Charlton M, Byrne KR, Gallegos-Orozco JF, Koptiuch C, Curtin K.
    Dig Dis Sci; 2016 Dec 01; 61(12):3627-3632. PubMed ID: 27655103
    [Abstract] [Full Text] [Related]

  • 10. Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands.
    Nakagawa H, Suzuki N, Hirata Y, Hikiba Y, Hayakawa Y, Kinoshita H, Ihara S, Uchino K, Nishikawa Y, Ijichi H, Otsuka M, Arita J, Sakamoto Y, Hasegawa K, Kokudo N, Tateishi K, Koike K.
    Proc Natl Acad Sci U S A; 2017 May 09; 114(19):E3806-E3815. PubMed ID: 28439013
    [Abstract] [Full Text] [Related]

  • 11. p53 protects against formation of extrahepatic biliary precancerous lesions in the context of oncogenic Kras.
    Nagao M, Mizukoshi K, Nakayama S, Namikawa M, Hiramatsu Y, Maruno T, Nakanishi Y, Tsuruyama T, Fukuda A, Seno H.
    Oncotarget; 2023 Mar 31; 14():276-279. PubMed ID: 36999984
    [Abstract] [Full Text] [Related]

  • 12. Isolation, culture and characterization of biliary epithelial cells from different anatomical levels of the intrahepatic and extrahepatic biliary tree from a mouse.
    Katayanagi K, Kono N, Nakanuma Y.
    Liver; 1998 Apr 31; 18(2):90-8. PubMed ID: 9588767
    [Abstract] [Full Text] [Related]

  • 13. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
    Mody K, Jain P, El-Refai SM, Azad NS, Zabransky DJ, Baretti M, Shroff RT, Kelley RK, El-Khouiery AB, Hockenberry AJ, Lau D, Lesinski GB, Yarchoan M.
    JCO Precis Oncol; 2022 Jun 31; 6():e2100510. PubMed ID: 35675577
    [Abstract] [Full Text] [Related]

  • 14. Mouse Model for Cholangiocarcinoma from Peribiliary Glands.
    Nakagawa H, Suzuki N, Koike K.
    Methods Mol Biol; 2019 Jun 31; 1905():237-245. PubMed ID: 30536105
    [Abstract] [Full Text] [Related]

  • 15. The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis.
    Kirimlioğlu H, Türkmen I, Başsüllü N, Dirican A, Karadağ N, Kirimlioğlu V.
    Turk J Gastroenterol; 2009 Mar 31; 20(1):41-7. PubMed ID: 19330734
    [Abstract] [Full Text] [Related]

  • 16. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
    Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A.
    J Pathol; 2005 Jul 31; 206(3):356-65. PubMed ID: 15892172
    [Abstract] [Full Text] [Related]

  • 17. Regional Differences in Human Biliary Tissues and Corresponding In Vitro-Derived Organoids.
    Rimland CA, Tilson SG, Morell CM, Tomaz RA, Lu WY, Adams SE, Georgakopoulos N, Otaizo-Carrasquero F, Myers TG, Ferdinand JR, Gieseck RL, Sampaziotis F, Tysoe OC, Ross A, Kraiczy JM, Wesley B, Muraro D, Zilbauer M, Oniscu GC, Hannan NRF, Forbes SJ, Saeb-Parsy K, Wynn TA, Vallier L.
    Hepatology; 2021 Jan 31; 73(1):247-267. PubMed ID: 32222998
    [Abstract] [Full Text] [Related]

  • 18. Expression of fatty-acid-binding protein 5 in intrahepatic and extrahepatic cholangiocarcinoma: the possibility of different energy metabolisms in anatomical location.
    Nakagawa R, Hiep NC, Ouchi H, Sato Y, Harada K.
    Med Mol Morphol; 2020 Mar 31; 53(1):42-49. PubMed ID: 31432248
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H, Kim D, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Hwang S, Kim KH, Song GW, Ahn CS, Lee JH, Hwang DW, Kim SC, Jang SJ, Hong SM, Kim TW, Ryoo BY.
    Eur J Cancer; 2019 Oct 31; 120():31-39. PubMed ID: 31476489
    [Abstract] [Full Text] [Related]

  • 20. Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities.
    Goeppert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud MM, Gornicka B, von Seth E, Reynolds GM, Franke A, Gotthardt DN, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide TJ, Weidemann S, Cheville JC, Mazza G, Hirschfield GM, Ponsioen CY, Bergquist A, Milkiewicz P, Lazaridis KN, Schramm C, Manns MP, Färkkilä M, Vogel A, International PSC Study Groupwww.ipscsg.org., Boberg KM, Schirmacher P, Karlsen TH.
    Hepatology; 2020 Oct 31; 72(4):1253-1266. PubMed ID: 31925805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.